Early Safety and Efficacy Profile of Homogeneously Dosed Salvage Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Recurrences After Low Dose Rate (LDR) Brachytherapy

Published:January 17, 2023DOI:


      • We retrospectively analyzed a cohort of 11 patients with a history of prior low dose rate brachytherapy who were treated with homogeneously dosed salvage stereotactic body radiotherapy (SBRT).
      • Three-year progression-free survival was 70.1%, while 3-year overall survival was 100%.
      • Late grade 2 and 3 genitourinary toxicity rates were 36.4% and 9.1%, respectively. Late grade 2 and 3 gastrointestinal toxicity rates were 0% and 9.1%, respectively.
      • Homogeneously dosed prostate SBRT can serve as a safe and effective salvage treatment for local recurrences following low dose rate (LDR) brachytherapy.



      We set out to evaluate the safety and efficacy of homogeneously dosed salvage stereotactic body radiation therapy (SBRT) for intraprostatic recurrences following low dose rate (LDR) brachytherapy.

      Patients and Methods

      An institutional prostate SBRT database was interrogated for patients treated between January 2018 and December 2021 with salvage SBRT for intraprostatic recurrences who were previously treated with LDR brachytherapy. Patients received 30 to 34 Gy in 5 fractions to the prostate with a simultaneous integrated boost of 34 to 37.5 Gy to gross disease. The maximum urethral dose allowed was 34 Gy. Toxicities were graded using Common Terminology Criteria for Adverse Events, version 5.0.


      Eleven patients met our study's inclusion criteria with a median follow-up time of 37.9 months (range, 24.3-51.8 months). Median time between LDR brachytherapy and salvage SBRT was 7 years (range, 2-11 years) with a median PSA of 3.15 ng/mL (range, 0.90-9.83) at the time of salvage radiation. All 11 patients were alive at the time of last follow-up. Our 3-year Kaplan-Meier progression-free survival rate was 70.1%. Median time to recurrence was 24.1 months (range, 18.7-29.7 months). Late (≥3 months) grade 1, 2, and 3 urinary toxicity rates were 27.3%, 36.4%, and 9.1%, respectively. Late (≥3 months) grade 1, 2, and 3 gastrointestinal toxicity rates were 18.2%, 0%, and 9.1%, respectively.


      Homogeneous salvage SBRT to the prostate with urethral dose minimization has a favorable safety and efficacy profile for treating intra-prostatic recurrences following LDR brachytherapy. This may represent an ideal form of salvage SBRT for re-irradiation.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. National Comprehensive Cancer Network Prostate Cancer (Version 1.2023). National Comprehensive Cancer Network®. Plymouth Meeting, Pennsylvania. Accessed October 7, 2022 Available online:

        • Tetreault-Laflamme A
        • Crook J
        • Hamm J
        • et al.
        Long-term prostate specific antigen stability and predictive factors of failure after permanent seed prostate brachytherapy.
        J Urol. 2018; 199: 120-125
        • Stone NN
        • Unger P
        • Crawford ED
        • Stock RG
        Diagnosis and management of local recurrence after low-dose-rate brachytherapy.
        Brachytherapy. 2015; 14: 124-130
        • Stone NN
        • Stock RG
        • White I
        • Unger P
        Patterns of local failure following prostate brachytherapy.
        J Urol. 2007; 177: 1759-1764
        • Lo AC
        • Morris WJ
        • Pickles T
        • Keyes M
        • McKenzie M
        • Tyldesley S
        Patterns of recurrence after low-dose-rate prostate brachytherapy: a population-based study of 2223 consecutive low- and intermediate-risk patients.
        Int J Radiat Oncol Biol Phys. 2015; 91: 745-751
        • Salerno KE
        • Turkbey B
        • Lindenberg L
        • et al.
        Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer.
        Brachytherapy. 2022; 21: 442-450
        • Valle LF
        • Lehrer EJ
        • Markovic D
        • et al.
        A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).
        Eur Urol. 2021; 80: 280-292
        • Bianco FJ
        • Scardino PT
        • Stephenson AJ
        • DiBlasio CJ
        • Fearn PA
        • Eastham JA
        Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
        Int J Radiat Oncol Biol Phys. 2005; 62: 448-453
        • Stephenson AJ
        • Eastham JA
        Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.
        J Clin Oncol. 2005; 23: 8198-8203
        • Fuller D
        • Wurzer J
        • Shirazi R
        • et al.
        Retreatment for local recurrence of prostatic carcinoma after prior therapeutic irradiation: efficacy and toxicity of HDR-Like SBRT.
        Int J Radiat Oncol Biol Phys. 2020; 106: 291-299
        • Pasquier D
        • Martinage G
        • Janoray G
        • et al.
        Salvage stereotactic body radiation therapy for local prostate cancer recurrence after radiation therapy: a retrospective multicenter study of the GETUG.
        Int J Radiat Oncol Biol Phys. 2019; 105: 727-734